Admittedly, it's not hard to create a basket of too-cheap health care stocks, today, and almost every one of these stories has a sizable "but." In the case of CareFusion (NYSE:CFN), though, slimming down that "but" seems relatively manageable. The company still has a ways to go in improving its returns on capital, but CareFusion's market positioning should make solid returns achievable. However, Wall Street presently gives CareFusion little credit.
A Mixed Start to the Year
For its first fiscal quarter, CareFusion reported that revenue rose 4%. Growth was led by the "Medical Systems" business at 9%, while the "Procedural Solutions" business saw revenue decline 2%. Dispensing technologies, which is part of Medical Systems, saw 16% reported topline growth. Infusion was surprisingly strong at 7%, while respiratory care and specialty disposables were laggards.
Follow this link for the full article:
http://stocks.investopedia.
No comments:
Post a Comment